CA3051829A1 — Methods for the administration of certain vmat2 inhibitors
Assigned to Neurocrine Biosciences Inc · Expires 2018-08-02 · 8y expired
What this patent protects
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy- 1,3,4,6,7,1 lb-hexahydro-2H-pyrido[2,l-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant ther…
USPTO Abstract
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy- 1,3,4,6,7,1 lb-hexahydro-2H-pyrido[2,l-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.